<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006120</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068134</org_study_id>
    <secondary_id>FRE-GERCOR-TAXMAX-SOO-1</secondary_id>
    <secondary_id>EU-20029</secondary_id>
    <nct_id>NCT00006120</nct_id>
  </id_info>
  <brief_title>Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Randomized Study of Two Different Schedules of Docetaxel or Paclitaxel for Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Randomized phase II trial to compare the effectiveness of two different regimens of
      docetaxel or paclitaxel in treating women who have unresectable locally advanced or
      metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the response rate, progression free survival, and overall survival in women with
           unresectable locally advanced or metastatic breast cancer treated with two different
           schedules of docetaxel or paclitaxel.

        -  Compare the toxicities and pharmacoeconomics of these four regimens in these patients.

        -  Compare the quality of life of patients treated with these four regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified by center, age,
      ECOG performance status, hormone receptor status (positive vs negative), metastasis to liver
      (yes vs no), and presence of disease progression following anthracyclines (yes vs no).

      Patients are randomized to one of four treatment arms.

        -  Arm I: Patients receive docetaxel IV over 1 hour on day 1.

        -  Arm II: Patients receive paclitaxel IV over 3 hours on day 1.

        -  Arm III: Patients receive docetaxel IV over 1 hour on days 1, 8, 15, 22, 29, and 36.

        -  Arm IV: Patients receive paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, and 36.

      Courses repeat every 3 weeks (arms I and II) or every 8 weeks (arms III and IV) in the
      absence of disease progression or unacceptable toxicity.

      Quality of life is assessed prior to treatment and then every 8 weeks.

      PROJECTED ACCRUAL: A total of 165 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven unresectable locally advanced or metastatic breast cancer

               -  Refractory or relapsed disease after neoadjuvant or adjuvant anthracyclines

          -  At least one bidimensionally measurable lesion

          -  No brain metastasis

          -  No bone metastases, lymphangitis carcinomatous, ascites, or pleural effusion as sole
             site of metastatic disease

          -  Hormone receptor status:

               -  Known hormone receptor status

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 75

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  ECOG 0-2 OR

          -  Karnofsky 60-100%

        Life expectancy:

          -  At least 12 weeks

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  AST and ALT no greater than 2.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase no greater than 2.5 times ULN

          -  Bilirubin normal

        Renal:

          -  Creatinine no greater than 1.5 times ULN

        Cardiovascular:

          -  No uncontrolled angina or arrhythmia

          -  No myocardial infarction within the past 6 months

          -  No New York Heart Association class III or IV heart disease

        Other:

          -  No sensitive neuropathy worse than grade 2

          -  No other significant, uncontrolled medical or psychiatric condition

          -  No serious active infection

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other prior malignancy except treated nonmelanomatous skin cancer or carcinoma in
             situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior specific antitumoral immunotherapy

        Chemotherapy:

          -  See Disease Characteristics

          -  No prior taxanes

          -  At least 4 weeks since other prior specific antitumoral chemotherapy

        Endocrine therapy:

          -  At least 4 weeks since prior specific antitumoral hormonal therapy

        Radiotherapy:

          -  At least 4 weeks since prior specific antitumoral radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  No other concurrent experimental medication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Gligorov, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Tenon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier d'Antibes</name>
      <address>
        <city>Antibes</city>
        <zip>06606</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Floreal</name>
      <address>
        <city>Bagnolet</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre D'Oncologie Du Pays-Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>F-64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.G. Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Fontenoy</name>
      <address>
        <city>Chartres</city>
        <zip>28018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Laennec</name>
      <address>
        <city>Creil</city>
        <zip>60109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Intercommunal De Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Drevon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Jeanne d'Arc - service de Radiotherapie Oncologie</name>
      <address>
        <city>Gien</city>
        <zip>45500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Desgenettes - Service de Medecine Interne</name>
      <address>
        <city>Lyon</city>
        <zip>69998</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Radiotherapie et Oncologie Saint-Faron</name>
      <address>
        <city>Mareuil Les Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame de Bon Secours</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Meulan</name>
      <address>
        <city>Meulan</city>
        <zip>78250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intercommunal Hospital</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68051</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Hartmann</name>
      <address>
        <city>Neuilly sur Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Hospital of Paris</name>
      <address>
        <city>Neuilly Sur Seine</city>
        <zip>F-92202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Geoffroy St. Hillaire</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ste - Marie</name>
      <address>
        <city>Pontoise</city>
        <zip>95301</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique De Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>F-51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre du Rouget</name>
      <address>
        <city>Sarcelles</city>
        <zip>95250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Orangerie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Fleming</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Ville D'Esch-sur-Alzette</name>
      <address>
        <city>Esch-sur-Alzette</city>
        <zip>L-4005</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 23, 2008</last_update_submitted>
  <last_update_submitted_qc>July 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2008</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

